Aurobindo Pharma under USFDA scrutiny
Posted by
www.biotecnika.org
Aurobindo has seen intense scrutiny on the manufacturer process of
valsartan, an anti-hypertension drug, that was found to contain
carcinogenic impurities. Apart from Aurobindo, those impurities were
detected in several other batches manufactured by drug makers.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-under-usfda-scrutiny/articleshow/71915368.cms
Subscribe to:
Post Comments (Atom)
Post a Comment